The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Cooksley, Graham ^a  

^a Royal Brisbane and Womens Hospital Research Foundation   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; LAMIVUDINE; MACROGOL; RIBAVIRIN;

ASIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INFECTION RATE; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0141526143     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00327-1     Document Type: Conference Paper

References (16)

1. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-522.
2. Thomas HC, Lok AS, Carreno V, Farrell G, Tanno H, Perez V, Dusheiko GM, Cooksley G, Ryff JC. Comparative study of three doses of Interferon alpha2a in chronic active hepatitis B. J Viral Hepat 1994;1:139-148.
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med 1993;119:312-323.
4. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of Lamivudine for chronic hepatitis B. N Engl J Med 1998;339:6-18.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Meal 1999;341:1256-1263.
6. Liaw Y-F, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B clearance after emergence of YMDD motif mutation during Lamivudine therapy. Hepatology 1999;30:567-572.
7. Lau DT-Y, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with Lamivudine. Hepatology 2000;32:834-838.
8. Xu ZX, Hoffman J, Patel I, Joubert P, Hoffmann-La-Roche In. Single dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEGIFN) and interferon alpha2a (IFN alpha2a) to healthy subjects. Hepatology 1998;28(Suppl):702A.
9. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, et al. Multinational evaluation of the efficacy and safety of once-weekly Peginterferon cc2a (PEG (40K)IFNa2a) in patients with chronic hepatitis C (CHC) with compensated cirrhosis. N Engl J Med 2000;343:1673-1680.
10. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alpha2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
11. Lindsay KL, Trepo C, Heintges T, Shiffmann ML, Gordon SC, Hoefs JC, et al. The Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alpha2b to interferon alpha2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
12. Cooksley WGE, Piratvisuth T, Wang YJ, Mahachi V, Chao YC, Tanwandee T, et al. 40 Kd PegInterferon alpha 2A (Pegasys) efficacy and safety results, from a phase 11, randomized actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B. American Association for the Study of Liver Disease, October 27-31, Dallas, TX, USA; 2001.
13. Cooksley WGE, Piratvisuth T, Wang YJ, Mahachi V, Chao YC, Tanwandee T, et al. Evidence for the efficacy of PegInterferon alpha 2A (40Kd) (Pegasys) in the treatment of HBeAntigen positive chronic hepatitis B and impact of baseline factors. European Association for the Study of the Liver, Madrid, 19 April; 2002.
14. Cooksley WGE, Piratvisuth R, Lee S-D, Mahachai V, Chao Y-C, Tanwandee T, et al. Peginterferon α-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Vir Hepatitis 2003;10:298-305.
15. Schiff ER, Karayalcin S, Grimm I, Perillo R, Dienstag J, Husa P, et al. A placebo controlled study of Lamivudine and interferon alpha2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28:388A.
16. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. International Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.